Manages acute pain severe enough to require an opioid analgesic. ANDA 220865, held by Msn. Tapentadol Hydrochloride.
As of Nov 16, 2026, ANDA 220865 (Tapentadol Hydrochloride), held by Msn, was first approved by FDA on Sep 3, 2026, with 0 approved supplements and 0 published complete response letters.
Tapentadol tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dose or duration, and persist over the course of therapy, reserve opioid analgesics, including tapentadol tablets for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Pediatric use information is approved for Collegium Pharmaceutical, Inc.’s NUCYNTA tablets.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 3, 2026 | Original application | Approved | None posted |
| Tapentadol HydrochlorideEQ 50MG BASE · tablet;oral | Tapentadol Hydrochloride | Rx |
| Tapentadol HydrochlorideEQ 75MG BASE · tablet;oral | Tapentadol Hydrochloride | Rx |
| Tapentadol HydrochlorideEQ 100MG BASE · tablet;oral | Tapentadol Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters